Journals / Anadolu Kardiyoloji Dergisi / 2010 / Cilt: 10 - Sayı: 2

Umut verici yeni bir inotropik ajan: Levosimendan

A promising new inotrope: Levosimendan

Pages
176–182
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review summarizes the evidence from current scientific literature including our recent trials regarding the mechanism of action, efficiency and the use of levosimendan.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Intravenous positive inotropic agents are commonly used to treat the patients with acute decompensated heart failure due to left ventricular systolic dysfunction.
📊
Key Findings & Data:Although these agents seem to be beneficial for improving symptoms of heart failure in the short-term; it has been reported that they are associated with increased mortality and morbidity.
💡
Conclusion & Impact:This review summarizes the evidence from current scientific literature including our recent trials regarding the mechanism of action, efficiency and the use of levosimendan.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Intravenous positive inotropic agents are commonly used to treat the patients with acute decompensated heart failure due to left ventricular systolic dysfunction. Although these agents seem to be beneficial for improving symptoms of heart failure in the short-term; it has been reported that they are associated with increased mortality and morbidity. Levosimendan is a new calcium sensitizer and K-ATP channel opener, has emerged as an alternative option of pharmacologic inotropic support in patients with decompensated heart failure. Recent reports on levosimendan's use in severe heart failure demonstrated that this agent is more favorable drug compared with conventional inotropic agents, though its better profile in terms of myocardial efficiency has not been completely understood. This review summarizes the evidence from current scientific literature including our recent trials regarding the mechanism of action, efficiency and the use of levosimendan.

Özet

Pozitif inotropik ajanlar sol ventrikül sistolik disfonksiyonuna bağlı dekompanse kalp yetersizliği tedavisinde sık olarak kullanılmaktadır. İnotropik ajan olarak kullanılan fosfodiesteraz inhibitörleri ve beta-adrenerjik agonistler, kalp yetersizliği semptomlarını kısa süreliğine etkili olarak düzelttiği halde, bu ilaçların kullanımının mortalite ve morbiditede artış yaptığı bildirilmiştir. Levosimendan yeni bir kalsiyum duyarlaştırıcısı ve K-ATP kanal açıcısı olup, dekompanse kalp yetersizliği hastalarında alternatif bir inotropik ajan olarak ortaya çıkmıştır. Yapılan son çalışmalar, miyokardiyal etkinliği tam anlaşılmamış olmasına rağmen, diğer konvansiyonel inotropik ajanlara kıyasla, ileri kalp yetersizliğinde levosimendan kullanımının daha uygun olduğunu ortaya koymuştur. Bu derleme, çeşitli klinik durumlarda levosimendan kullanımının etkinliği üzerine yapılan bilimsel çalışmaları özetlemektedir.

🔖

Cite This Article

FOTBOLCU, H., DUMAN, D. (2022). Umut verici yeni bir inotropik ajan: Levosimendan. Anadolu Kardiyoloji Dergisi, Cilt: 10 - Sayı: 2, 176–182. https://ajindex.com/articles/436787

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Krum H, Liew D. New and emerging drug therapies for the management of acute heart failure. Intern Med J 2003; 33: 515-20. doi:10.1046/j.1445-5994.2003.00483.x PMid:14656255 2. Nieminen MS, Harjola VP. Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 2005; 96 (Suppl 6A): 5G-10G. doi:10.1016/j.amjcard.2005.07.015 PMid:16181818 3. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 2002; 4: 515-29. doi:10.1016/S1388-9842(02)00041-7 4. Packer M. The search for the ideal positive inotropic agent. N Engl J Med 1993; 329: 201-2. doi:10.1056/NEJM199307153290310 PMid:8515793 5. Pagel PS, Harkin CP, Hettrick DA, Warltier DC. Levosimendan (OR1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology 1994; 81: 974-87. doi:10.1097/00000542-199410000-00025 PMid:7943849 6. Udvary E, Papp JG, Végh A. Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction. Br J Pharmacol 1995; 114: 656-61. PMid:7735692 PMCid:1510011 7. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006; 113: 305-15. doi:10.1161/CIRCULATIONAHA.105.542407 PMid:16418450 8. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998; 98: 2141-7. PMid:9815868 9. Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, Nagren K, et al. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997; 61: 596-607. doi:10.1016/S0009-9236(97)90139-9 10. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca 2 sensitizer, activates the glibenclamide-sensitive K-channel in rat arterial myocytes. Eur J Pharmacol 1997; 333: 249-59. doi:10.1016/S0014-2999(97)01108-4 11. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2001; 37: